Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

33.55 +3.08 (+10.09%)
Streaming Delayed Price Updated: 2:03 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
A Look Ahead: Stoke Therapeutics's Earnings Forecast ↗
 
Via Benzinga
News headline image
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's... 
Via Chartmill
News headline image
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
News headline image
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces CEO Transition
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.